Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors
Maria Lucia Iacovino(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Felice Crocetto(University of Naples Federico II), Carminia Maria Della Corte(University of Campania "Luigi Vanvitelli"), Luca Pompella(University of Campania "Luigi Vanvitelli"), Marco De Felice(Istituto Superiore di Sanità), Ciro Imbimbo(University of Naples Federico II), Francesco Chiancone(Ospedale Antonio Cardarelli), Giuseppe Tirino(University of Campania "Luigi Vanvitelli"), Erika Di Zazzo(University of Molise), Ferdinando De Vita(University of Campania "Luigi Vanvitelli"), Biagio Barone(Ospedale San Paolo), Chiara Carmen Miceli(University of Campania "Luigi Vanvitelli")
Cited by 50
Related Papers
ROS in cancer therapy: the bright side of the moon
|Experimental & Molecular Medicine|2020|2.2k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|347
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|285
Unravelling the Complexity of T Cell Abnormalities in Common Variable Immunodeficiency
|The Journal of Immunology|2007|274